TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12005116
Drug: Sodium lauryl
Normalized name: sodium lauryl sulfate
DrugBank: Sodium lauryl sulfate (DB00815)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium lauryl sulphate (SLS) patch test
Study: 7822659
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone tapered over 8 days with intramuscular placebo
Study: 7822659
Drug: Intramuscular methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular methylprednisolone sodium acetate and oral placebo
Study: 2120986
Drug: ioversol-320 (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: ioversol-320 (32 g iodine)
Study: 2120986
Drug: iohexol-300 (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol-300 (45 g iodine)
Study: 30649973
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy (P + C)
Study: 29070849
Drug: Rituximab-containing therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab-containing therapies
Study: 23574571
Drug: Anti-wrinkle cream
Normalized name: CAFFEINE 1300 mg in 130 g / COLLAGEN, SOLUBLE, FISH SKIN 6500 mg in 130 g / HYALURONIC ACID 6500 mg in 130 g / RETINOL 1170 mg in 130 g / SHEA BUTTER 5200 mg in 130 g / JOJOBA OIL 1300 mg in 130 g TOPICAL CREAM [AOAO Retiol Anti-Wrinkle Cream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-wrinkle cream containing retinol, hyaluronic acid, and dihydroxymethylchromone
Study: 21059877
Drug: RME followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RME followed by TPA therapy plus extraction of deciduous canines (RME/TPA/EC group, 40 subjects)
Study: 21059877
Drug: TPA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPA therapy plus extraction of deciduous canines (TPA/EC group, 25 subjects)
Study: 21059877
Drug: No orthodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No orthodontic treatment (Control group, CG, 30 subjects)
Study: 8932837
Drug: Cyclophosphamide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (120 mg/kg), mitoxantrone (60 mg/m2), and melphalan (140 mg/m2) followed by autologous bone marrow transplantation (ABMT)
Study: 8932837
Drug: Cyclophosphamide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (120 mg/kg), mitoxantrone (60 mg/m2), and melphalan (140 mg/m2) followed by ABMT
Study: 28505956
Drug: Non‐invasive Spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐invasive Spinal Decompression Therapy (NSDT)
Study: 28505956
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of electrotherapy, deep friction massage, and stabilization exercise (Control Group)
Study: 25384624
Drug: Split virion
Normalized name: Influenza A virus A/Kansas/14/2017 (H3N2)-like virus strain split virion hemagglutinin Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split virion vaccine
Study: 25384624
Drug: Whole virion
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole virion vaccine
Study: 25384624
Drug: Split virion
Normalized name: Influenza A virus A/Kansas/14/2017 (H3N2)-like virus strain split virion hemagglutinin Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split virion vaccine with anti-TNF-α therapy
Study: 23068310
Drug: sucking-oral sucrose-tucking
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sucking-oral sucrose-tucking
Study: 23068310
Drug: sucking-oral sucrose
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sucking-oral sucrose
Study: 23068310
Drug: oral sucrose-tucking
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral sucrose-tucking
Study: 19366972
Drug: Intravenous glulisine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glulisine insulin
Study: 19366972
Drug: Subcutaneous glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous glargine and glulisine
Study: 19366972
Drug: Subcutaneous NPH
Normalized name: INSULIN,NPH,BEEF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous NPH and regular insulin
Study: 15305945
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of inhaled budesonide
Study: 15305945
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with inhaled budesonide
Study: 9386112
Drug: Intravenous vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous vasopressin (0.1 U/min)
Study: 7910053
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with thymosin alpha 1, interferon-alpha, and zidovudine
Study: 7910053
Drug: Zidovudine alone
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine alone or associated with single agents
Study: 3064642
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (100 mg/day) for 10 days
Study: 3064642
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules for 10 days
Study: 29347848
Drug: Intravaginal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal oxytocin gel
Study: 19595100
Drug: Screw canal
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screw canal preparation time
Study: 12734858
Drug: Gastrografin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrografin (100 ml)
Study: 10647721
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml intracameral, unpreserved, epinephrine‐free 1% lidocaine
Study: 9052889
Drug: Intrabrachial acetylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrabrachial acetylcholine (0.15, 0.45, 1.5, 4.5, and 15 microg/100 mL per minute)
Study: 9052889
Drug: L-arginine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (1 micromol/100 mL per minute)
Study: 9052889
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 microg/100 mL per minute)
Study: 9052889
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (1, 2, and 4 microg/100 mL per minute)
Study: 8346005
Drug: Trivalent cold‐adapted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent cold‐adapted recombinant influenza vaccine
Study: 25394440
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl (50 μg) and normal saline (10 mL)
Study: 25394440
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl (50 μg) and bupivacaine (0.5%; 10 mL)
Study: 23328343
Drug: Multidisciplinary program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary program consisting of cognitive-behavior therapy and exercise training
Study: 9469675
Drug: Ziprasidone 20
Normalized name: ziprasidone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 20 mg administered under fasting conditions (treatment A)
Study: 9469675
Drug: Ziprasidone 20
Normalized name: ziprasidone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 20 mg administered directly after a standard high-fat breakfast (treatment B)
Study: 9469675
Drug: Ziprasidone 20
Normalized name: ziprasidone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 20 mg administered 2 hours after a standard high-fat breakfast (treatment C)
Study: 27424688
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 22 mg/kg/day
Study: 2209678
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) 2 mg/kg/day
Study: 20430115
Drug: Usual primary
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual primary prevention care plus bespoke lifestyle support (treatment)
Study: 12438948
Drug: Sirolimus (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (5 mg daily after a 15 mg loading dose, concentration-controlled to keep 24-hr trough levels at 10 to 12 ng/mL for 6 months and 5 to 10 ng/mL thereafter)
Study: 12438948
Drug: Cyclosporine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (6 to 8 mg/kg per day in divided doses, concentration-controlled to keep 12-hr troughs of 200 to 250 ng/mL)
Study: 7781416
Drug: Surgery combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery combined with chemotherapy and radiotherapy
Study: 6104451
Drug: KWD 2131
Approvals — FDA: no, EMA: no, PMDA: no
Description: KWD 2131 (0.5 mg to 12 mg)
Study: 6104451
Drug: Terbutaline (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (0.05 mg to 1.2 mg)
Study: 28239805
Drug: Closed-loop target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop target controlled infusion (CLTCI) of cisatracurium
Study: 28239805
Drug: Continuous pump
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous pump injection
Study: 15545949
Drug: Fluticasone/Salmeterol (FP/S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/Salmeterol (FP/S) combination
Study: 15545949
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with a free combination of an inhaled corticosteroid and a long-acting beta2-agonist (TA)
Study: 9731837
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg prostaglandin E2 intracervical gel (Prepidil) every 6 hours for 2 doses
Study: 9731837
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg prostaglandin E2 slow release vaginal pessary (Cervidil)
Study: 7984606
Drug: Ultrahigh-frequency electromagnetic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrahigh-frequency electromagnetic radiation (UHF) therapy combined with specific chemicals, 10 sessions using a YAVOR device at 6.4 and 7.1 mm.
Study: 7984606
Drug: Ultrahigh-frequency electromagnetic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrahigh-frequency electromagnetic radiation (UHF) therapy combined with specific chemicals.
Study: 7984606
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (drug therapy alone).
Study: 2722718
Drug: Latamoxef 2
Normalized name: latamoxef
DrugBank: Latamoxef (DB04570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Latamoxef 2 g
Study: 2291659
Drug: Cefmetazole 2
Normalized name: cefmetazole 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefmetazole 2 g
Study: 798282
Drug: Cyclic chemotherapy
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic chemotherapy with Arabinosyl Cytosine (ARA C), Vincristine, and Prednisone
Study: 28132007
Drug: ibobbly app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ibobbly app (acceptance‐based therapy) over 6 weeks
Study: 14963464
Drug: sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sildenafil 50 mg
Study: 8971288
Drug: Effervescent ranitidine
Normalized name: ranitidine Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent ranitidine 150 mg
Study: 8971288
Drug: Effervescent ranitidine
Normalized name: ranitidine Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent ranitidine 300 mg
Study: 8971288
Drug: Standard ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ranitidine 150 mg
Study: 8971288
Drug: Standard ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ranitidine 300 mg
Study: 6360571
Drug: Control night
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control night (no CPAP treatment).
Study: 28744557
Drug: Active pulsed
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active pulsed magnetic stimulation (PMS) for 8 weeks (twice/week)
Study: 28744557
Drug: Sham pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham pulsed magnetic stimulation for 8 weeks (twice/week)
Study: 25079861
Drug: Colestilan 3
Normalized name: colestilan
DrugBank: Colestilan chloride (DB11634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestilan 3 - 12 g/day
Study: 25079861
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 - 40 mg/day
Study: 15863540
Drug: Preoperative vaginal
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative vaginal preparation with povidone-iodine
Study: 11967501
Drug: Isosorbide 5‐mononitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide 5‐mononitrate 40 mg 4 hours or 10 hours before the operation
Study: 8275477
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no preoperative treatment)
Study: 11967501
Drug: Isosorbide 5‐mononitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide 5‐mononitrate 40 mg
Study: 2757664
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid sustained release formulation (Contrheuma retard) 300 mg initial dose and 350 mg retard formulation
Study: 2757664
Drug: Standard ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ASA solution for intravenous administration
Study: 2757664
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid sustained release formulation (Contrheuma retard)
Study: 337694
Drug: Novocain treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novocain treatment (2% procain 5ml, intramuscular injections, 3 times a week, 12 injections a month)
Study: 337694
Drug: Gerovital H3
Normalized name: Vitamin H3
DrugBank: Procaine (DB00721)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gerovital H3 treatment according to A. Aslan's method
Study: 30755016
Drug: Exercise non-responders
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise non-responders (defined as change in peak oxygen uptake <1 ml/kg/min)
Study: 26770664
Drug: D-cycloserine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine (50 mg) given 30 minutes prior to weekly group social skills training for 10 weeks
Study: 26770664
Drug: Placebo given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given 30 minutes prior to weekly group social skills training for 10 weeks
Study: 25132784
Drug: 4-L sulfa-free
Normalized name: 2-Sulfa-4-methylpyrimidine
DrugBank: Sulfamerazine (DB01581)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-L sulfa-free polyethylene glycol (4-L SF-PEG)
Study: 25132784
Drug: 2-L polyethylene
Normalized name: Iron(2+) L-ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-L polyethylene glycol solution with ascorbic acid (2-L PEG + Asc)
Study: 22556186
Drug: Personal health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal health record (PHR)‐linked medications module
Study: 19173689
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 50 mg
Study: 17253995
Drug: Partial body-weight-supported
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial body-weight-supported treadmill training (PBWSTT), conducted twice a week for 6 weeks
Study: 16022849
Drug: Mifepristone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 10 mg (3 courses) with condoms
Study: 9832286
Drug: Cefepime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (2 g intravenously every 12 h)
Study: 7858479
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (10 mg/day)
Study: 2627107
Drug: Alpress osmotic
Normalized name: Ez2go Osmotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpress osmotic tablet (prazosin)
Study: 825744
Drug: Calcium in
Normalized name: Avail Calcium Intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium in combination with vitamin D2 (calciferol), given orally
Study: 25645164
Drug: Parent-augmented One-Session
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-augmented One-Session Treatment (A-OST)
Study: 25645164
Drug: Child-focused One-Session
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child-focused One-Session Treatment (OST)
Study: 24423417
Drug: 68.8 mg
Normalized name: glycerin 68.8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68.8 mg lidocaine with 50 μg epinephrine plus 0.9 M mannitol (5 mL formulation)
Study: 24423417
Drug: 68.8 mg
Normalized name: glycerin 68.8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68.8 mg lidocaine with 50 μg epinephrine (1.72 mL formulation)
Study: 22233822
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MC) at 10 or 20 mg/m² every 3 weeks
Study: 15586886
Drug: G0-micronucleus (MN)
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: G0-micronucleus (MN) assay with low dose-rate (LDR) irradiation (4 mGy/min)
Study: 15586886
Drug: G0-micronucleus (MN)
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: G0-micronucleus (MN) assay with high dose-rate (HDR) irradiation (1 Gy/min)
Study: 15586886
Drug: Dose-rate sparing
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-rate sparing index
Study: 1489037
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg diclofenac (intramuscular)
Study: 3930688
Drug: Liposyn at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposyn at 0.34 g
Study: 3930688
Drug: Liposyn at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposyn at 0.68 g
Study: 3930688
Drug: Modified Liposyn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Liposyn at 0.68 g/kg/day
Study: 3930688
Drug: Reference group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference group (fat-free parenteral nutrition)
Study: 25884981
Drug: Medium dose:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose: 50 mg Zn, 75 mcg Se, 250 IU vitamin E
Study: 25884981
Drug: Low dose:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose: 25 mg Zn, 50 mcg Se, 250 IU vitamin E
Study: 25884981
Drug: Standard supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard supplement (control)
Study: 22080020
Drug: 150 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/kg PFA
Study: 22080020
Drug: 750 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg/kg PFA
Study: 22080020
Drug: 1,500 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,500 mg/kg PFA
Study: 10680104
Drug: Thiopental 2.5
Normalized name: thiopental 2.5 g intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 2.5 +/- 1.0 mg/kg
Study: 10680104
Drug: Propofol 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.6 +/- 0.6 mg/kg
Study: 1712323
Drug: Mifepristone, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone, 25 mg five times at 12-hour intervals (n = 192)
Study: 1712323
Drug: Mifepristone, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone, 600 mg as a single dose (n = 193)
Study: 6179101
Drug: Indobufen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen (100 mg i.v.)
Study: 27513257
Drug: Lidocaine with
Normalized name: Lidocaine with Tegaderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with epinephrine (Group L)
Study: 27513257
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline solution with epinephrine (Group S)
Study: 25167690
Drug: Micronutrient supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient supplementation (MMS) 'Sprinkles' (powdered formulation of iron, vitamins A and C, folic acid, and zinc)
Study: 20642549
Drug: Ticagrelor 100
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 100 mg twice daily
Study: 20642549
Drug: Ticagrelor 300
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 300 mg once daily
Study: 20642549
Drug: Ticagrelor 50-600
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 50-600 mg once daily
Study: 18095612
Drug: Domestic Acarbose
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Domestic Acarbose capsule (DAC)
Study: 15735805
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy (Aspirin, Clopidogrel, Dipyridamole - ACD)
Study: 15735805
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Aspirin and Clopidogrel (AC)
Study: 15735805
Drug: Aspirin, Clopidogrel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, Clopidogrel, Dipyridamole (ACD)
Study: 9851729
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin (IVIg) in patients with DM
Study: 9851729
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin (IVIg) in patients with IBM
Study: 9851729
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin (IVIg) in specific muscle groups in IBM patients